Compare AdaptHealth Corp (AHCO) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AdaptHealth Corp vs Boston Scientific Corporation — how do they compare? AdaptHealth Corp trades at $10.05 (market cap $1.38B), while Boston Scientific Corporation trades at $44.73 (market cap $67.33B). The key difference: Boston Scientific Corporation is far larger — about 48.8× AdaptHealth Corp's market cap, and AdaptHealth Corp is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| AHCO | BSX | |
|---|---|---|
Market Cap | $1.38B | $67.33B |
Sector | Health | Health |
52-Week High | $13.38 | $108.14 |
52-Week Low | $8.68 | $42.68 |
Enterprise Value | $3.33B | $76.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
Boston Scientific (BSX) trades at $45.30, showing modest daily gains of 0.35% amid a bearish technical trend. The company demonstrates strong fundamentals with consistent earnings beats, revenue growth from $12.7B in 2022 to $20.1B in 2025, and robust profitability margins. Recent news highlights a significant price decline from all-time highs, creating valuation opportunities despite competitive pressures in key segments like electrophysiology.
The investment outlook remains positive based on strong analyst consensus (88% buy ratings) and a $73.63 price target implying 63% upside. Key risks include growth deceleration in core products and market volatility. Fundamentals support long-term value, but investors should monitor execution against revised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AdaptHealth Corp
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
